Risk of movement disorders with antipsychotic drugs in patients with schizophrenia or depressive disorders
Objective: To compare the risk of movement disorders with antipsychotic drugs (APDs) in patients suffering from Schizophrenia or Depressive Disorders. Background: APDs are well-known causes…Frequency of echogenic abnormality of the substantia nigra is increased in methamphetamine users
Objective: To investigate structural abnormality of the substantia nigra (SN) in methamphetamine users using transcranial sonography (TCS). Background: Epidemiologic studies suggest that chronic use of…Drug induced parkinsonism: Role of functional imaging and follow up
Objective: Retrospective study of the outcome of patients with new onset parkinsonism with a history of exposure of a drug known to cause parkinsonism prior…Valproate-induced reversible parkinsonism – A case series
Objective: To describe a case series of valproate (VPA)-induced parkinsonism and increase awareness for this condition. Background: VPA as a cause of parkinsonism has been…Effect of intra-striatal 6-OHDA lesion on extra-striatal structures in the mouse
Objective: Characterization of extra-striatal manifestations in the 6-hydroxydopamine (6-OHDA) Parkinson's disease (PD) animal model. Background: PD is a neurodegenerative disorder characterized by progressive loss of…A comparative study of clinical profile of patients of drug induced parkinsonism with idiopathic Parkinson’s disease
Objective: Drug induced parkinsonism (DIP), caused by various group of drugs, is second most common etiology of parkinsonism after Idiopathic Parkinson's disease (IPD). No major…Incidental finding of drug-induced movement disorder
Objective: Recognizing a drug-induced movement disorder is critical as only stopping using over the counter dopamine-blocking medications such as metoclopramide can reverse or improve clinical…Three distinct cases of methamphetamine induced movement disorders
Objective: To detail three cases of methamphetamine induced movement disorders with unique clinical phenotypes. Background: MA is an addictive psychostimulant that affects both the central…
- « Previous Page
- 1
- …
- 8
- 9
- 10